Payment overview · 2025
General Payments
$155.01
9 reported records · 7 companies
Healthcare provider profile · identity verified
Alan J Watanabe, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · COLUMBUS, IN · NPI 1518961507
Verified facts
What the public records show
CMS Open Payments records show Alan J Watanabe, M.D. received $155.01 in general payments during 2025 across 9 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 24.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.70 | 24.3% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.35 | 17.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.84 | 12.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.73 | 12.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.72 | 11.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.53 | 11.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.14 | 11.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $117.31 | 7 |
| Education | $37.70 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $37.70 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $27.35 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 41 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 90 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
174 | 40 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
166 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 780 | 218 |
| Atorvastatin Calcium | Atorvastatin Calcium | 607 | 170 |
| Losartan Potassium | Losartan Potassium | 604 | 176 |
| Amlodipine Besylate | Amlodipine Besylate | 442 | 133 |
| Levothyroxine Sodium | Levothyroxine Sodium | 398 | 100 |
| Metoprolol Succinate | Metoprolol Succinate | 377 | 95 |
| Omeprazole | Omeprazole | 361 | 117 |
| Lisinopril | Lisinopril | 346 | 102 |
| Tamsulosin Hcl | Tamsulosin Hcl | 320 | 97 |
| Simvastatin | Simvastatin | 292 | 81 |
| Metformin Hcl | Metformin Hcl | 233 | 69 |
| Alendronate Sodium | Alendronate Sodium | 221 | 65 |
| Pravastatin Sodium | Pravastatin Sodium | 204 | 63 |
| Gabapentin | Gabapentin | 202 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 196 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 178 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 178 | 49 |
| Furosemide | Furosemide | 177 | 57 |
| Synthroid | Levothyroxine Sodium | 174 | 40 |
| Ozempic | Semaglutide | 168 | 26 |
| Eliquis | Apixaban | 166 | 41 |
| Meloxicam | Meloxicam | 156 | 45 |
| Tramadol Hcl | Tramadol Hcl | 151 | 26 |
| Potassium Chloride | Potassium Chloride | 147 | 44 |
| Glimepiride | Glimepiride | 142 | 42 |
| Carvedilol | Carvedilol | 131 | 38 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 116 | 33 |
| Allopurinol | Allopurinol | 111 | 34 |
| Ezetimibe | Ezetimibe | 109 | 36 |
| Trazodone Hcl | Trazodone Hcl | 108 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 106 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 104 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 27 |
| Mounjaro | Tirzepatide | 97 | 19 |
| Atenolol | Atenolol | 94 | 28 |
| Jardiance | Empagliflozin | 90 | 23 |
| Montelukast Sodium | Montelukast Sodium | 88 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 31 |
| Sertraline Hcl | Sertraline Hcl | 80 | 25 |
| Finasteride | Finasteride | 73 | 23 |
| Donepezil Hcl | Donepezil Hcl | 70 | 20 |
| Ipratropium Bromide | Ipratropium Bromide | 70 | 36 |
| Metformin Hcl Er | Metformin Hcl | 67 | 21 |
| Irbesartan | Irbesartan | 65 | 15 |
| Spironolactone | Spironolactone | 65 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 12 |
| Chlorthalidone | Chlorthalidone | 57 | 20 |
| Famotidine | Famotidine | 57 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 57 | 12 |
| Clonidine Hcl | Clonidine Hcl | 56 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 49 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 17 |
| Celecoxib | Celecoxib | 46 | 12 |
| Colchicine | Colchicine | 46 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | suppressed |
| Alprazolam | Alprazolam | 44 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | 11 |
| Farxiga | Dapagliflozin Propanediol | 41 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 15 |
| Prednisone | Prednisone | 40 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | 13 |
| Meclizine Hcl | Meclizine Hcl | 39 | 16 |
| Mirtazapine | Mirtazapine | 39 | 12 |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 37 |
| Nebivolol Hcl | Nebivolol Hcl | 35 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Hydrocortisone | Hydrocortisone | 34 | 13 |
| Lovastatin | Lovastatin | 34 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 12 |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 15 |
| Rybelsus | Semaglutide | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Valsartan | Valsartan | 25 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Cefdinir | Cefdinir | 23 | 22 |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Linzess | Linaclotide | 17 | 11 |
| Torsemide | Torsemide | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 14 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Bystolic | Nebivolol Hcl | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | 11 |
| Lagevrio (Eua) | Molnupiravir | 11 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $155.01 · 9 records | Boehringer Ingelheim Pharmaceuticals, Inc. | FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, NURTEC ODT, REXULTI, VOQUEZNA, VRAYLAR, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error